Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rigel’s fostamatinib meets main goal in phase 3 study in chronic ITP
The study, which is the first of two double-blind trials in the FIT Phase 3 clinical program, demonstrated that 18% of patients receiving fostamatinib achieved a stable platelet
The study, which is the first of two double-blind trials in the FIT Phase 3 clinical program, demonstrated that 18% of patients receiving fostamatinib achieved a stable platelet
The PERSIST-2 trial demonstrated statistically significant improvement in spleen volume reduction (SVR) with pacritinib compared to best available therapy (BAT), including ruxolitinib. The results were generated from 221
Synacthen Depot is a depot formulation of Synacthen (tetracosactide), a synthetic 24 amino acid melanocortin receptor agonist. It is approved and marketed outside the US for several autoimmune
ND0612L is a low-dose continuous subcutaneously administered levodopa/carbidopa liquid formulation. Parkinson’s disease is a progressive neurodegenerative illness characterized by reduced dopamine levels in the brain. The multicenter, double-blind, placebo-controlled
Mylan co-developed the product candidate with Indian biopharmaceutical company Biocon. Trastuzumab is one of the six biologic products co-developed by both the firms for the worldwide marketplace. Mylan
The collaboration aims to generate constant Fc domains with antigen-binding activity (Fcabs) that can bind to transporters in the blood–brain barrier. Through the platform, the companies said, Fcabs
The deal will see Pfizer acquire the development and commercialization rights to AstraZeneca’s late-stage small molecule anti-infectives business in most markets outside the US. It includes the commercialization
Novartis claims that the Expand study is the largest study ever undertaken in SPMS. More than 1,600 people with SPMS from 31 countries participated in the study. They
The priority review status shortens the review clock to six months from the usual 10 months. The agency's action date (PDUFA) is 23 February 2017. Clovis Oncology’s application
The company is seeking approval of Darzalex, in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone, to treat adult patients with relapsed multiple myeloma (MM) who have